On the 6th of January 2023 the Food and Drug Administration (FDA) approved Lecanemab-irmb through the accelerated approval pathway to treat Alzheimer’s disease. There has been rigorous efforts to combat this dreaded disease. Lecanemab is a second drug now approved for the treatment of Alzheimer’s disease. The first, named aducanumab, was earlier approved by FDAContinue reading “Alzheimer’s disease: treatments at last”